Maltodextrin
As of the edition of 20 October 2026, Maltodextrin is a drug: in active development; acts on CALCR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2017
- Kind
- Unknown
- Registered trials
- 5, 1 stopped early
- Disease areas
- Digestive system; Heart and blood vessels; Nervous system; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CALCR | Calcitonin receptor | P30988 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 3 | 2 | 1 | 1 | 0 |
| Phase 4 | 2 | 1 | 1 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Hamilton Health Sciences | Lead sponsor of trials | 2025 to now |